Marie-Andrée GAMACHE joins Pierre Fabre Laboratories as CEO of the Medical Care
31 March 2025
Castres (France), March 31, 2025 – Pierre Fabre Laboratories has announced the appointment of Marie-Andrée Gamache as Chief Executive Officer (CEO) of its Medical Care. In this capacity, Marie-Andrée Gamache joins the Group’s Executive Committee and reports to Eric Ducournau, Group CEO.
A Canadian national, Marie-Andrée Gamache has spent over 25 years in the pharmaceutical industry, in a wide range of leadership roles at country, regional and global levels across Europe, North America, Asia, Middle East and Africa. She holds a proven track record of broad leadership and P&L experience, with expertise from early pipeline to commercialization.
Before joining Pierre Fabre, Marie-Andrée was Country President and Managing Director for Novartis UK and Ireland. Previously, she had rejoined Novartis in 2019 as Head of the Oncology division for the Middle East and Africa region, after spending four years at Merck KGAA as Managing Director in Belgium and Sub-Sahara Africa
Marie-Andrée Gamache will bring her energetic leadership, international stature and wide pharmaceutical experience to Pierre Fabre Medical Care. In 2024, the latter achieved revenues of 1,3 billion euros spread across oncology (39%), dermatology (15%), primary care (26%) and family health care (13%). Marie-Andrée’s main priorities will be to fuel the strong momentum of the oncology portfolio through expansion to new indications and territories, to optimize revenue and profitability growth for the balance of the Medical Care portfolio, and to prepare for the next decade by supervising the R&D pipeline development in targeted oncology, medical dermatology and rare diseases.
We are thrilled to welcome Marie-Andrée whose international background and expertise especially in oncology will undoubtedly drive our Medical Care business forward. All along her career, Marie-Andrée has demonstrated an outstanding commitment to patient-centricity, medical innovation, excellence in execution and team building. We look forward to reaching new milestones together.
I’m delighted to join Pierre Fabre Laboratories and its Medical Care teams who have achieved so much in the past 5 years. I’m passionate about creating the right environment to accelerate medical innovation and improve access to medicines for patients worldwide. Pierre Fabre Laboratories’ purpose is to care for each single person to make the world better. I could not think of a better match and I’m now looking forward to lead Pierre Fabre Medical Care to the next level up.
About Pierre Fabre Laboratories
Pierre Fabre Laboratories is the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, and Même Cosmetics. Its Medical Care activity covers 4 main therapeutic fields: oncology, dermatology, primary care and family health care.
For over 40 years, Pierre Fabre Laboratories has established itself as an international player in oncology, mastering the entire value chain from R&D to marketing. Its portfolio of oncology specialties covers colorectal, breast, lung and skin cancers, as well as certain hematologic malignancies and precancerous dermatological conditions such as actinic keratosis. In 2024, Pierre Fabre Laboratories’ revenues in oncology came to 520 million euros, over 90% of which were generated by international sales, out of a total sales figure of 3.1 billion euros.
Based in southwest France since its creation, Pierre Fabre Laboratories manufactures more than 90% of its products in France and employs 10,200 people worldwide. In 2024, its R&D budget amounted to 220 million euros, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. There are currently 10 research and development programs underway dedicated to targeted therapies in oncology.
Pierre Fabre Laboratories’ majority shareholder (86%) is an eponymous Foundation, which is recognized by the French government as being a public-interest foundation. Employees constitute the company’s other shareholder. This capital structure guarantees the company’s independence, long-term vision and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world.
Pierre Fabre Laboratories’ CSR policy has been assessed by AFNOR Certification and has been awarded the “Exemplary” level of its CSR label (ISO 26 000 standard for sustainable development).
For more information, visit www.pierre-fabre.com, @Pierre Fabre Oncology
Media Contact
Laure Bregeon-Sgandurra
+33 6 32 54 92 01
Laure.Sgandurra@pierre-fabre.com